CA2881656C - Diagnosis and treatment of autism spectrum disorder - Google Patents
Diagnosis and treatment of autism spectrum disorder Download PDFInfo
- Publication number
- CA2881656C CA2881656C CA2881656A CA2881656A CA2881656C CA 2881656 C CA2881656 C CA 2881656C CA 2881656 A CA2881656 A CA 2881656A CA 2881656 A CA2881656 A CA 2881656A CA 2881656 C CA2881656 C CA 2881656C
- Authority
- CA
- Canada
- Prior art keywords
- subject
- asd
- composition
- 4eps
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000029560 autism spectrum disease Diseases 0.000 title claims abstract description 348
- 238000011282 treatment Methods 0.000 title abstract description 138
- 238000003745 diagnosis Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 129
- 208000024891 symptom Diseases 0.000 claims abstract description 62
- 241000606124 Bacteroides fragilis Species 0.000 claims description 163
- DWZGLEPNCRFCEP-UHFFFAOYSA-N 4-ethylphenyl sulfate Chemical compound CCC1=CC=C(OS(O)(=O)=O)C=C1 DWZGLEPNCRFCEP-UHFFFAOYSA-N 0.000 claims description 120
- 230000036765 blood level Effects 0.000 claims description 59
- 230000003542 behavioural effect Effects 0.000 claims description 58
- 210000002700 urine Anatomy 0.000 claims description 58
- 230000001965 increasing effect Effects 0.000 claims description 55
- 241000606125 Bacteroides Species 0.000 claims description 53
- 244000005709 gut microbiome Species 0.000 claims description 47
- 230000002496 gastric effect Effects 0.000 claims description 40
- 208000020706 Autistic disease Diseases 0.000 claims description 38
- 206010003805 Autism Diseases 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 230000007423 decrease Effects 0.000 claims description 23
- 230000002550 fecal effect Effects 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 21
- 230000003247 decreasing effect Effects 0.000 claims description 21
- 230000003870 intestinal permeability Effects 0.000 claims description 21
- 239000006041 probiotic Substances 0.000 claims description 21
- 235000018291 probiotics Nutrition 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 20
- 229920001282 polysaccharide Polymers 0.000 claims description 20
- 239000005017 polysaccharide Substances 0.000 claims description 20
- 238000012937 correction Methods 0.000 claims description 19
- 230000007812 deficiency Effects 0.000 claims description 19
- 230000000529 probiotic effect Effects 0.000 claims description 19
- 230000009429 distress Effects 0.000 claims description 14
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 10
- 241000095588 Ruminococcaceae Species 0.000 claims description 7
- 208000004998 Abdominal Pain Diseases 0.000 claims description 6
- 208000002881 Colic Diseases 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 208000019902 chronic diarrheal disease Diseases 0.000 claims description 6
- 241000589013 Alcaligenaceae Species 0.000 claims description 5
- 241000606215 Bacteroides vulgatus Species 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 241000609971 Erysipelotrichaceae Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 63
- 208000019901 Anxiety disease Diseases 0.000 abstract description 26
- 230000036506 anxiety Effects 0.000 abstract description 20
- 230000001575 pathological effect Effects 0.000 abstract description 17
- 239000002207 metabolite Substances 0.000 description 245
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 69
- 239000011780 sodium chloride Substances 0.000 description 69
- 230000004060 metabolic process Effects 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 60
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 59
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 42
- 210000002966 serum Anatomy 0.000 description 42
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 230000006399 behavior Effects 0.000 description 33
- -1 mamiose Substances 0.000 description 31
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 29
- 210000001072 colon Anatomy 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 230000004075 alteration Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 16
- 230000005856 abnormality Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 229940100601 interleukin-6 Drugs 0.000 description 16
- 230000006977 prepulse inhibition Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 15
- 230000006735 deficit Effects 0.000 description 14
- 241001112696 Clostridia Species 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 241001112693 Lachnospiraceae Species 0.000 description 12
- 210000001578 tight junction Anatomy 0.000 description 12
- 241000736262 Microbiota Species 0.000 description 11
- 102000000591 Tight Junction Proteins Human genes 0.000 description 11
- 108010002321 Tight Junction Proteins Proteins 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- WGNAKZGUSRVWRH-UHFFFAOYSA-M p-cresol sulfate(1-) Chemical compound CC1=CC=C(OS([O-])(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-M 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 9
- 241001141113 Bacteroidia Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 102000003899 claudin 8 Human genes 0.000 description 9
- 108090000239 claudin 8 Proteins 0.000 description 9
- 229920003045 dextran sodium sulfate Polymers 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 230000036278 prepulse Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 229940076279 serotonin Drugs 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 8
- 102000004359 Claudin-15 Human genes 0.000 description 8
- 108090000997 Claudin-15 Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000007529 anxiety like behavior Effects 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000004579 marble Substances 0.000 description 8
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 8
- 238000007492 two-way ANOVA Methods 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 7
- 241000589538 Pseudomonas fragi Species 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 230000003252 repetitive effect Effects 0.000 description 7
- 230000003997 social interaction Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 208000036640 Asperger disease Diseases 0.000 description 6
- 201000006062 Asperger syndrome Diseases 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 238000010152 Bonferroni least significant difference Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000009227 behaviour therapy Methods 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 208000024825 childhood disintegrative disease Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000004144 purine metabolism Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000024188 startle response Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 208000027244 Dysbiosis Diseases 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 208000006289 Rett Syndrome Diseases 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960002086 dextran Drugs 0.000 description 5
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 5
- YEKFYCQGYMVFKR-UHFFFAOYSA-N docosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCC=CC=CC=CC=CC=CC(O)=O YEKFYCQGYMVFKR-UHFFFAOYSA-N 0.000 description 5
- 230000007140 dysbiosis Effects 0.000 description 5
- 230000004129 fatty acid metabolism Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003137 locomotive effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 210000004910 pleural fluid Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000003989 repetitive behavior Effects 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- HNICUWMFWZBIFP-BSZOFBHHSA-N 13-HODE Chemical compound CCCCCC(O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-BSZOFBHHSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- NPDSHTNEKLQQIJ-ZJHFMPGASA-N alpha-dimorphecolic acid Chemical compound CCCCC\C=C/C=C/C(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-ZJHFMPGASA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- GKJZMAHZJGSBKD-JPDBVBESSA-N dihomolinoleic acid Chemical compound CCCCC\C=C/C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-JPDBVBESSA-N 0.000 description 4
- NPDSHTNEKLQQIJ-UHFFFAOYSA-N dimorphecolic acid Natural products CCCCCC=CC=CC(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 4
- 235000019126 equol Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 229960000367 inositol Drugs 0.000 description 4
- 210000005027 intestinal barrier Anatomy 0.000 description 4
- 230000007358 intestinal barrier function Effects 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002705 metabolomic analysis Methods 0.000 description 4
- 230000001431 metabolomic effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-M palmitoleate Chemical compound CCCCCC\C=C/CCCCCCCC([O-])=O SECPZKHBENQXJG-FPLPWBNLSA-M 0.000 description 4
- 229940014662 pantothenate Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- UTYVDVLMYQPLQB-UHFFFAOYSA-N phenylacetylglycine Chemical compound OC(=O)CNC(=O)CC1=CC=CC=C1 UTYVDVLMYQPLQB-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- WHBJOLRFIRVGDM-UHFFFAOYSA-M potassium;(4-ethylphenyl) sulfate Chemical compound [K+].CCC1=CC=C(OS([O-])(=O)=O)C=C1 WHBJOLRFIRVGDM-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007637 random forest analysis Methods 0.000 description 4
- 208000013406 repetitive behavior Diseases 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 238000002121 ultrasonic speckle velocimetry Methods 0.000 description 4
- 230000004143 urea cycle Effects 0.000 description 4
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 208000013404 behavioral symptom Diseases 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 150000002066 eicosanoids Chemical class 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229940049918 linoleate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000004006 stereotypic behavior Effects 0.000 description 3
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YAPRWCFMWHUXRS-UHFFFAOYSA-N (2-hydroxyphenyl) propanoate Chemical compound CCC(=O)OC1=CC=CC=C1O YAPRWCFMWHUXRS-UHFFFAOYSA-N 0.000 description 2
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 description 2
- FYSSBMZUBSBFJL-VIFPVBQESA-N (S)-3-hydroxydecanoic acid Chemical compound CCCCCCC[C@H](O)CC(O)=O FYSSBMZUBSBFJL-VIFPVBQESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LXUGKKVCSTYZFK-HYNUQJCBSA-N 1-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@@H](O)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O LXUGKKVCSTYZFK-HYNUQJCBSA-N 0.000 description 2
- PYVRVRFVLRNJLY-MZMPXXGTSA-N 1-oleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-MZMPXXGTSA-N 0.000 description 2
- MXAFDFDAIFZFET-CZDOQZASSA-N 1-stearoyl-sn-glycero-3-phospho-1D-myo-inositol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O MXAFDFDAIFZFET-CZDOQZASSA-N 0.000 description 2
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 2
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 2
- UGAGPNKCDRTDHP-UHFFFAOYSA-M 16-hydroxyhexadecanoate Chemical compound OCCCCCCCCCCCCCCCC([O-])=O UGAGPNKCDRTDHP-UHFFFAOYSA-M 0.000 description 2
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 description 2
- YNOWULSFLVIUDH-UHFFFAOYSA-N 3-dehydrocarnitine Chemical compound C[N+](C)(C)CC(=O)CC([O-])=O YNOWULSFLVIUDH-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- TUHVEAJXIMEOSA-UHFFFAOYSA-N 4-guanidinobutanoic acid Chemical compound NC(=[NH2+])NCCCC([O-])=O TUHVEAJXIMEOSA-UHFFFAOYSA-N 0.000 description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000692822 Bacteroidales Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- VJXUJFAZXQOXMJ-UHFFFAOYSA-N D-1-O-Methyl-muco-inositol Natural products CC12C(OC)(C)OC(C)(C)C2CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 VJXUJFAZXQOXMJ-UHFFFAOYSA-N 0.000 description 2
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101000785517 Homo sapiens Tight junction protein ZO-3 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 2
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 description 2
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 108090000304 Occludin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000179547 Pelophylax shqipericus Species 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000692844 Prevotellaceae Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000036353 Rett disease Diseases 0.000 description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100026640 Tight junction protein ZO-3 Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-L azelaate(2-) Chemical compound [O-]C(=O)CCCCCCCC([O-])=O BDJRBEYXGGNYIS-UHFFFAOYSA-L 0.000 description 2
- 229940067597 azelate Drugs 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 229940000640 docosahexaenoate Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229940093497 ergothioneine Drugs 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000008938 immune dysregulation Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940040452 linolenate Drugs 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-M margarate Chemical compound CCCCCCCCCCCCCCCCC([O-])=O KEMQGTRYUADPNZ-UHFFFAOYSA-M 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-L pimelate(2-) Chemical compound [O-]C(=O)CCCCCC([O-])=O WLJVNTCWHIRURA-UHFFFAOYSA-L 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- MZPWKJZDOCIALD-UHFFFAOYSA-N pyrocatechol sulfate Chemical compound OC1=CC=CC=C1OS(O)(=O)=O MZPWKJZDOCIALD-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- LSFYCRUFNRBZNC-UHFFFAOYSA-N (2-hydroxyphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1O LSFYCRUFNRBZNC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YTBKOFZZSHCXGJ-QRPNPIFTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;phenol Chemical compound OC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YTBKOFZZSHCXGJ-QRPNPIFTSA-N 0.000 description 1
- SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- XEBKSQSGNGRGDW-GJWDQICYSA-N (Z,9R,10R)-9,10-dihydroxyoctadec-12-enoic acid Chemical compound CCCCC\C=C/C[C@@H](O)[C@H](O)CCCCCCCC(O)=O XEBKSQSGNGRGDW-GJWDQICYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
- PRTJOPDOMKJHSD-UHFFFAOYSA-N 2-aminobutanoic acid butanoic acid Chemical compound C(CCC)(=O)O.NC(C(=O)O)CC PRTJOPDOMKJHSD-UHFFFAOYSA-N 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- NOCWDMQAHCQAKS-UHFFFAOYSA-N 2-hydroxyoctadeca-2,4-dienoic acid Chemical class CCCCCCCCCCCCCC=CC=C(O)C(O)=O NOCWDMQAHCQAKS-UHFFFAOYSA-N 0.000 description 1
- FGYZAECYNNGYAN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;propane-1,2-diol Chemical compound CC(O)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O FGYZAECYNNGYAN-UHFFFAOYSA-N 0.000 description 1
- JVGVDSSUAVXRDY-UHFFFAOYSA-M 3-(4-hydroxyphenyl)lactate Chemical compound [O-]C(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-M 0.000 description 1
- QHKABHOOEWYVLI-UHFFFAOYSA-M 3-methyl-2-oxobutanoate Chemical compound CC(C)C(=O)C([O-])=O QHKABHOOEWYVLI-UHFFFAOYSA-M 0.000 description 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-M 3-methyl-2-oxovalerate Chemical compound CCC(C)C(=O)C([O-])=O JVQYSWDUAOAHFM-UHFFFAOYSA-M 0.000 description 1
- LZBBEECOKDJNLB-UHFFFAOYSA-N 3-phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1.OC(=O)CCC1=CC=CC=C1 LZBBEECOKDJNLB-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- PLKZZSKEJCNYEQ-UHFFFAOYSA-N 4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=C(O)C=C1 PLKZZSKEJCNYEQ-UHFFFAOYSA-N 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- ZFLGNXXKOHFLGG-MDTBIHKOSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidine-2,4-dione;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O ZFLGNXXKOHFLGG-MDTBIHKOSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KDMSVYIHKLZKET-UHFFFAOYSA-N 8-hydroxyoctanoic acid Chemical compound OCCCCCCCC(O)=O KDMSVYIHKLZKET-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- WYLVVXFASZFOEN-UHFFFAOYSA-N C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.N1C=NC=2N=CNC2C1=O Chemical compound C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.C(C=CCCC)(=O)O.N1C=NC=2N=CNC2C1=O WYLVVXFASZFOEN-UHFFFAOYSA-N 0.000 description 1
- XPCRGNKQOAWNMC-UHFFFAOYSA-N C(CCCCCCCCC(=O)O)(=O)O.C(CCCCCCCCC(=O)O)(=O)O.OC(C(=O)O)CCC(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCCCC(=O)O)(=O)O Chemical compound C(CCCCCCCCC(=O)O)(=O)O.C(CCCCCCCCC(=O)O)(=O)O.OC(C(=O)O)CCC(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCCCC(=O)O)(=O)O XPCRGNKQOAWNMC-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- VWGJOJWNVVTCMS-UHFFFAOYSA-M CC(=O)C([O-])=O.C[N+](C)(C)CCO Chemical compound CC(=O)C([O-])=O.C[N+](C)(C)CCO VWGJOJWNVVTCMS-UHFFFAOYSA-M 0.000 description 1
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 description 1
- 101150029784 CTDSPL gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001081259 Erysipelotrichia Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001086785 Homo sapiens Occludin Proteins 0.000 description 1
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 1
- ZHLWCBHWYUISFY-UHFFFAOYSA-N Hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)C(O)C1=CC=CC=C1 ZHLWCBHWYUISFY-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- JSJWCHRYRHKBBW-UHFFFAOYSA-N N-carbamoyl-beta-alanine Chemical compound NC(=O)NCCC(O)=O JSJWCHRYRHKBBW-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical compound CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 description 1
- CXTATJFJDMJMIY-UHFFFAOYSA-N O-octanoylcarnitine Chemical compound CCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C CXTATJFJDMJMIY-UHFFFAOYSA-N 0.000 description 1
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 description 1
- JGSILCHQHQWDPN-ZAUOCLJLSA-N OC(=O)[C@@H](N)CC(O)=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O Chemical compound OC(=O)[C@@H](N)CC(O)=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JGSILCHQHQWDPN-ZAUOCLJLSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 102100032604 Occludin Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000692843 Porphyromonadaceae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 244000097202 Rathbunia alamosensis Species 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 241000692845 Rikenellaceae Species 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 101100187065 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nif1 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 241001331069 Thismia Species 0.000 description 1
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 241000385736 bacterium B Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- GJBRTCPWCKRSTQ-UHFFFAOYSA-N decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.OC(=O)CCCCCCCCC(O)=O GJBRTCPWCKRSTQ-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- TVIDDXQYHWJXFK-UHFFFAOYSA-L dodecanedioate(2-) Chemical compound [O-]C(=O)CCCCCCCCCCC([O-])=O TVIDDXQYHWJXFK-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- CATMPQFFVNKDEY-AAEUAGOBSA-N gamma-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-AAEUAGOBSA-N 0.000 description 1
- 108010054509 gamma-glutamyltryptophan Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- LBVXQJLRCKNHRF-UHFFFAOYSA-N hexadecanoic acid;8-hydroxyoctanoic acid Chemical compound OCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O LBVXQJLRCKNHRF-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000007540 host microbe interaction Effects 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000002442 hydroxyeicosatetraenoic acids Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 235000019226 kombucha tea Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000037340 metabolism of cofactors and vitamins Effects 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- TWHMVKPVFOOAMY-UHFFFAOYSA-N octanedioic acid Chemical compound OC(=O)CCCCCCC(O)=O.OC(=O)CCCCCCC(O)=O TWHMVKPVFOOAMY-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- YKEKYBOBVREARV-UHFFFAOYSA-N pentanedioic acid Chemical compound OC(=O)CCCC(O)=O.OC(=O)CCCC(O)=O YKEKYBOBVREARV-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- AHUJXUYEELPHRR-UHFFFAOYSA-N pyrimidine;1h-pyrimidine-2,4-dione Chemical compound C1=CN=CN=C1.O=C1C=CNC(=O)N1 AHUJXUYEELPHRR-UHFFFAOYSA-N 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000002098 selective ion monitoring Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000009156 sensorimotor behavior Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241000344485 unclassified Bacteroidales Species 0.000 description 1
- 241001352226 unclassified Bacteroidia Species 0.000 description 1
- LWBHHRRTOZQPDM-UHFFFAOYSA-N undecanedioic acid Chemical compound OC(=O)CCCCCCCCCC(O)=O LWBHHRRTOZQPDM-UHFFFAOYSA-N 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
- G01N2800/7076—Amino acid metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
- G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261694679P | 2012-08-29 | 2012-08-29 | |
| US61/694,679 | 2012-08-29 | ||
| PCT/US2013/057148 WO2014036182A2 (en) | 2012-08-29 | 2013-08-28 | Diagnosis and treatment of autism spectrum disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2881656A1 CA2881656A1 (en) | 2014-03-06 |
| CA2881656C true CA2881656C (en) | 2023-07-11 |
Family
ID=50184623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2881656A Active CA2881656C (en) | 2012-08-29 | 2013-08-28 | Diagnosis and treatment of autism spectrum disorder |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10220089B2 (enExample) |
| EP (1) | EP2890808A4 (enExample) |
| JP (2) | JP6679309B2 (enExample) |
| CN (2) | CN114949001A (enExample) |
| AU (2) | AU2013308826B2 (enExample) |
| CA (1) | CA2881656C (enExample) |
| WO (1) | WO2014036182A2 (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| BR112013002667B1 (pt) | 2010-08-04 | 2020-02-04 | Thomas Julius Borody | composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las |
| EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MX2016000293A (es) * | 2013-07-09 | 2016-06-21 | Stemina Biomarker Discovery Inc | Biomarcadores del trastrono del espectro autista. |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| EP3209803A4 (en) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| HK1244461A1 (zh) * | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| WO2016069792A1 (en) * | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| JP6611156B2 (ja) * | 2015-01-30 | 2019-11-27 | 史郎 栃谷 | 妊娠期母体腸内細菌攪乱による行動異常モデル動物の作製方法とその用途 |
| US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
| EP3268354B1 (en) | 2015-03-13 | 2020-05-06 | Mironova Innovations, LLC | Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds |
| EP3283086A4 (en) * | 2015-04-13 | 2019-04-24 | Ubiome Inc. | METHOD AND SYSTEM FOR MICROBIOMY-DERIVED DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO MICROBIOMIC FUNCTIONAL PROPERTIES |
| AU2016248050A1 (en) * | 2015-04-13 | 2017-11-09 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| AU2016250102A1 (en) * | 2015-04-13 | 2017-11-09 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| CN107949391B (zh) | 2015-05-14 | 2021-11-09 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| PT3297644T (pt) * | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| CN105213433A (zh) * | 2015-11-06 | 2016-01-06 | 王益超 | 一种用于治疗孤独症、复发性流产和不孕症的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN105543369B (zh) * | 2016-01-13 | 2020-07-14 | 金锋 | 精神障碍的生物标志物及其应用 |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2017197252A1 (en) * | 2016-05-13 | 2017-11-16 | Stemina Biomarker Discovery, Inc. | Autism subsets |
| WO2017205302A1 (en) | 2016-05-23 | 2017-11-30 | California Institute Of Technology | Regulate gut microbiota to treat neurodegenerative disorders |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| MX2019002918A (es) | 2016-09-16 | 2019-07-18 | Dyax Corp | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018089794A1 (en) * | 2016-11-11 | 2018-05-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for changing metabolite levels in a subject |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| BR112018076609B1 (pt) * | 2016-12-15 | 2023-02-14 | Société des Produits Nestlé S.A. | Composição alimentícia para animais de estimação, seus usos, e métodos não terapêutico para modular a quantidade e para medição de uma alteração na quantidade de pelo menos uma dentre bifidobacterium, lactobacillus ou clostridium perfringens |
| EP3579924A4 (en) * | 2017-02-07 | 2020-12-23 | California Institute of Technology | MODULATION OF THE INTESTINAL MICROBIOTE IN HUNTINGTON'S DISEASE AND RETT SYNDROME |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| WO2018152133A1 (en) * | 2017-02-14 | 2018-08-23 | California Institute Of Technology | Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenol sulfate in behavior and disease |
| EP3600349A4 (en) * | 2017-03-31 | 2020-09-30 | Axial Biotherapeutics, Inc. | SELECTIVE GUT SEQUESTRATION AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| WO2018187467A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| WO2018213204A1 (en) | 2017-05-15 | 2018-11-22 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| WO2018216912A1 (ko) * | 2017-05-26 | 2018-11-29 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 자폐증 진단방법 |
| WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| US11883155B2 (en) | 2017-07-05 | 2024-01-30 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| US11141089B2 (en) * | 2017-07-05 | 2021-10-12 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| US10939862B2 (en) * | 2017-07-05 | 2021-03-09 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| AU2018253466B2 (en) | 2017-07-17 | 2019-03-28 | smartDNA Pty Ltd | Method of diagnosing a dysbiosis |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US20230158084A1 (en) * | 2018-01-05 | 2023-05-25 | California Institute Of Technology | Probiotics, metabolites, and uses thereof |
| WO2019180263A2 (en) | 2018-03-22 | 2019-09-26 | Adare Pharmaceuticals Sas | New use of microbiological compositions |
| WO2020012467A2 (en) * | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CN109142744A (zh) * | 2018-07-26 | 2019-01-04 | 珠海中科先进技术研究院有限公司 | 一种自闭症谱系障碍诊断试剂盒 |
| CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| CA3118790A1 (en) | 2018-11-06 | 2020-05-14 | Stalicla Sa | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, asd phenotype 1 |
| US11676719B2 (en) * | 2018-12-20 | 2023-06-13 | Oregon Health & Science University | Subtyping heterogeneous disorders using functional random forest models |
| CN109706235A (zh) * | 2019-01-29 | 2019-05-03 | 广州康昕瑞基因健康科技有限公司 | 一种肠道微生物菌群的检测和分析方法及其系统 |
| CA3136303A1 (en) | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| WO2020206443A1 (en) * | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms |
| US20220373563A1 (en) * | 2019-04-23 | 2022-11-24 | Peking Union Medical College Hospital | Machine learning-based autism spectrum disorder diagnosis method and device using metabolite as marker |
| EP3965820A4 (en) | 2019-05-07 | 2023-02-08 | The Regents of the University of California | COMPOSITIONS AND METHODS TO PROMOTE HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY |
| CN110178787B (zh) * | 2019-05-08 | 2022-03-22 | 河南中医药大学 | 一种运用粪菌移植法建立自闭症大鼠模型的方法 |
| PE20221399A1 (es) | 2019-07-19 | 2022-09-15 | Finch Therapeutics Holdings Llc | Metodos y productos para el tratamiento de trastornos gastrointestinales |
| EP4041265A4 (en) * | 2019-10-11 | 2024-03-27 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS ASSOCIATED WITH ALTERED LEVELS OF METABOLITES CONCENTRATIONS |
| TWI870485B (zh) | 2019-10-21 | 2025-01-21 | 日商表飛鳴製藥股份有限公司 | 多形類桿菌６０３０之用途 |
| US20230026402A1 (en) * | 2019-10-22 | 2023-01-26 | Cornell University | Microbiota based therapies to promote mental health |
| WO2021126220A1 (en) * | 2019-12-19 | 2021-06-24 | Hill's Pet Nutrition, Inc. | Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines using tomato pomace and methods of identifying canines at risk of such conditions |
| US20230145281A1 (en) * | 2020-03-06 | 2023-05-11 | University Of Virginia Patent Foundation | System and method for predicting risk of diagnosis for autism spectrum disorder using neonatal analytics |
| CN111455076B (zh) * | 2020-04-17 | 2022-10-21 | 济南市儿童医院 | 用于儿童孤独症评估的口腔菌群微生物 |
| CN116547520A (zh) * | 2020-09-21 | 2023-08-04 | 分子优公司 | 孤独症谱系障碍的诊断与治疗方法 |
| KR20230074216A (ko) * | 2020-09-21 | 2023-05-26 | 몰레큘러 유 코포레이션 | 자폐 스펙트럼 장애의 진단 및 치료 방법 |
| CN117083062A (zh) * | 2020-10-19 | 2023-11-17 | 第二基因组公司 | 用于治疗孤独症谱系障碍的方法 |
| CN114544826B (zh) * | 2020-11-24 | 2023-12-08 | 重庆医科大学 | 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途 |
| EP4012414A1 (en) | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
| CN113069469B (zh) * | 2021-04-07 | 2022-12-13 | 上海市精神卫生中心（上海市心理咨询培训中心） | 调节性t细胞在制备治疗孤独症药物或细胞疗法中的应用 |
| CN114699423B (zh) * | 2022-02-16 | 2023-06-23 | 广州知易生物科技有限公司 | 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用 |
| CN114699424B (zh) * | 2022-02-16 | 2023-07-18 | 广州知易生物科技有限公司 | 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用 |
| CN114457153A (zh) * | 2022-03-15 | 2022-05-10 | 西安交通大学 | 一种孤独症血清神经元来源外泌体标志物chrm1的应用 |
| CN117598247A (zh) * | 2022-03-25 | 2024-02-27 | 天津中医药大学 | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 |
| CN114622026B (zh) * | 2022-04-02 | 2024-10-01 | 中南大学湘雅三医院 | 拟杆菌作为预测自闭症疗效的客观指标 |
| CN116990395A (zh) * | 2022-04-26 | 2023-11-03 | 中国科学院深圳先进技术研究院 | 一种基于粪便的阿尔兹海默症生物标志物及其应用 |
| CN115368300B (zh) * | 2022-10-27 | 2023-03-24 | 北京拓领博泰生物科技有限公司 | 用于tlr8抑制剂的化合物及其制备方法、应用 |
| CN115616227B (zh) * | 2022-11-18 | 2023-05-16 | 四川大学华西医院 | 吲哚-3-丙烯酰甘氨酸检测试剂的用途、诊断或辅助诊断慢性阻塞性肺病的试剂盒及系统 |
| US12005044B1 (en) | 2022-11-29 | 2024-06-11 | Autism Therapeutics Inc. | Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof |
| WO2025007066A1 (en) * | 2023-06-30 | 2025-01-02 | University Of Massachusetts | Biomarkers and methods related to fragile x syndrome |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
| US5951977A (en) | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| US7749509B2 (en) | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| US20060177424A1 (en) | 2003-08-29 | 2006-08-10 | Cobb Mark L | Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions |
| CA2586334A1 (en) | 2004-11-16 | 2006-06-08 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| GB0504096D0 (en) | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20100233312A9 (en) | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
| ES2473625T3 (es) | 2007-10-26 | 2014-07-07 | Brenda E. Moore | Composición probi�tica y métodos para inducir y mantener la pérdida de peso |
| DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
| CA2711608A1 (en) | 2008-01-09 | 2009-07-16 | Yale University | Mutations in contaction associated protein 2 (cntnap2) are associated with increased risk for ideopathic autism |
| EP2358370A2 (en) | 2008-11-13 | 2011-08-24 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
| WO2010111516A2 (en) | 2009-03-25 | 2010-09-30 | Whitehead Institute For Biomedical Research | Compositions and methods for inhibiting biofilms |
| US9050276B2 (en) * | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
| JP2013507394A (ja) | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| CA2797787C (en) * | 2010-04-29 | 2019-07-09 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
| US9707207B2 (en) | 2010-05-26 | 2017-07-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Method for diagnosing, preventing, and treating neurological diseases |
| WO2011153226A2 (en) | 2010-06-01 | 2011-12-08 | Moore Research Enterprises Llc | Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof |
| US20130115257A1 (en) | 2010-07-08 | 2013-05-09 | Katholieke Universiteit Leuven | Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |
| JP5931884B2 (ja) * | 2010-10-07 | 2016-06-08 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症の生菌療法 |
| US20120237482A1 (en) | 2011-03-18 | 2012-09-20 | Juan Rodriguez | Methods for treatment of neurological disorders by modulation of microglial activation |
| EP3569690B1 (en) | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US20150265661A1 (en) | 2012-04-13 | 2015-09-24 | Trustees Of Boston College | Prebiotic effect of sialyllactose |
| US10220089B2 (en) * | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| FI127671B (en) | 2014-05-28 | 2018-11-30 | Filip Scheperjans | Method for diagnostics of Parkinson’s disease |
| CN104546932A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| HK1244461A1 (zh) | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| WO2016069792A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| US20170360853A1 (en) | 2015-01-07 | 2017-12-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies |
| PT3297644T (pt) | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| WO2017205302A1 (en) | 2016-05-23 | 2017-11-30 | California Institute Of Technology | Regulate gut microbiota to treat neurodegenerative disorders |
| US11324717B2 (en) | 2016-06-22 | 2022-05-10 | Microbial Research Management Health Nv | Microbial carotenoids affecting gut microbial composition |
-
2013
- 2013-08-28 US US14/012,769 patent/US10220089B2/en active Active
- 2013-08-28 WO PCT/US2013/057148 patent/WO2014036182A2/en not_active Ceased
- 2013-08-28 JP JP2015530008A patent/JP6679309B2/ja active Active
- 2013-08-28 AU AU2013308826A patent/AU2013308826B2/en active Active
- 2013-08-28 CN CN202210623110.8A patent/CN114949001A/zh active Pending
- 2013-08-28 EP EP13832132.8A patent/EP2890808A4/en active Pending
- 2013-08-28 CN CN201380056909.2A patent/CN104768560A/zh active Pending
- 2013-08-28 CA CA2881656A patent/CA2881656C/en active Active
-
2018
- 2018-09-10 JP JP2018168982A patent/JP2019031497A/ja active Pending
- 2018-11-16 US US16/193,724 patent/US11052151B2/en active Active
-
2019
- 2019-07-18 AU AU2019206081A patent/AU2019206081B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6679309B2 (ja) | 2020-04-15 |
| AU2019206081A1 (en) | 2019-08-08 |
| AU2019206081B2 (en) | 2021-06-10 |
| AU2013308826B2 (en) | 2019-04-18 |
| CN104768560A (zh) | 2015-07-08 |
| US11052151B2 (en) | 2021-07-06 |
| EP2890808A2 (en) | 2015-07-08 |
| AU2013308826A1 (en) | 2015-02-26 |
| EP2890808A4 (en) | 2016-09-28 |
| CA2881656A1 (en) | 2014-03-06 |
| JP2019031497A (ja) | 2019-02-28 |
| US10220089B2 (en) | 2019-03-05 |
| US20190231871A1 (en) | 2019-08-01 |
| WO2014036182A2 (en) | 2014-03-06 |
| WO2014036182A3 (en) | 2014-05-01 |
| CN114949001A (zh) | 2022-08-30 |
| JP2015529668A (ja) | 2015-10-08 |
| US20140065132A1 (en) | 2014-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019206081B2 (en) | Diagnosis And Treatment Of Autism Spectrum Disorder | |
| Shan et al. | Gut microbiome-derived lactate promotes to anxiety-like behaviors through GPR81 receptor-mediated lipid metabolism pathway | |
| Kim et al. | Antibiotics-induced dysbiosis of intestinal microbiota aggravates atopic dermatitis in mice by altered short-chain fatty acids | |
| Berni Canani et al. | Skin, gut, and lung barrier: physiological interface and target of intervention for preventing and treating allergic diseases | |
| Barron et al. | Role of arginase 1 from myeloid cells in th2-dominated lung inflammation | |
| Verherstraeten et al. | The synergistic necrohemorrhagic action of Clostridium perfringens perfringolysin and alpha toxin in the bovine intestine and against bovine endothelial cells | |
| Coletto et al. | The role of the mucin-glycan foraging Ruminococcus gnavus in the communication between the gut and the brain | |
| Tian et al. | 919 syrup alleviates postpartum depression by modulating the structure and metabolism of gut microbes and affecting the function of the hippocampal GABA/glutamate system | |
| Huang et al. | Commensal microbe-derived propionic acid mediates juvenile social isolation-induced social deficits and anxiety-like behaviors | |
| Liang et al. | Escherichia coli triggers α-synuclein pathology in the LRRK2 transgenic mouse model of PD | |
| Li et al. | Congenitally underdeveloped intestine drives autism-related gut microbiota and behavior | |
| Yang et al. | Whole intestinal microbiota transplantation is more effective than fecal microbiota transplantation in reducing the susceptibility of DSS-induced germ-free mice colitis | |
| Anashkina et al. | Molecular mechanisms of aberrant neuroplasticity in autism spectrum disorders | |
| Hamade et al. | BATF3 protects against metabolic syndrome and maintains intestinal epithelial homeostasis | |
| US20230158084A1 (en) | Probiotics, metabolites, and uses thereof | |
| HK40079872A (en) | Diagnosis and treatment of autism spectrum disorder | |
| SEN et al. | Synthesis and initial evaluation of efficacy of olean-12-en-28-ol, 3 beta-pentacosanoate for the symptomatic treatment of multiple sclerosis | |
| Lebovitz | Modulation of Neurodevelopmental Outcomes using Lactobacillus in a Model of Maternal Microbiome Dysbiosis | |
| Gogoi | Neuroprotective Effect of Gut Microbiota Modulation in Alzheimer's Disease: a Preclinical Study | |
| Yang et al. | Prenatal Poly I: C exposure affects tryptophan-kynurenine metabolism associated with intestinal microbiome in female juvenile rats | |
| Latham | Infectious Disease, Age, and Environmental Contaminants As Neurotoxicants That Modulate Glia and Contribute to Neurodegenerative Pathology | |
| Corsetto et al. | Nutrient deprivation induces lipid alterations and reduction of invasivity in triple negative breast cancer cells | |
| Germundson-Hermanson | Intracranial Mast Cell Activation and Central Histaminergic Dysregulation in Food Allergy-Associated Neuropathology and Behavioral Changes | |
| Daniele | Sex differences in stroke dysbiosis in rodent models of focal cortical ischemia | |
| Huang et al. | Enterococcus-derived cytolysin exacerbates ischemic stroke by disrupting the blood–brain barrier via NLRP3 activation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170901 |
|
| EEER | Examination request |
Effective date: 20170901 |
|
| EEER | Examination request |
Effective date: 20170901 |
|
| EEER | Examination request |
Effective date: 20170901 |
|
| EEER | Examination request |
Effective date: 20170901 |
|
| EEER | Examination request |
Effective date: 20170901 |